In This Section
Dr. Olson aims to improve diagnostics and treatment of bone marrow failure (BMF) syndromes, and to improve clinical hematopoietic stem cell transplantation (HSCT) outcomes. He conducts clinical trials of HSCT for non-malignant hematologic diseases. His laboratory explores both basic and translational research focused on genomics of BMF and the impact of BMF on hematopoietic niche function during HSCT.
Dr. Olson's clinical efforts focus on pediatric hematopoietic stem cell transplantation (HSCT), with a specific emphasis on HSCT for patients with inherited and acquired bone marrow failure. Through his combined clinical activities in the Bone Marrow Failure Center within the Division of Hematology and the Blood and Marrow Transplant Section within the Division of Oncology, his goal is to facilitate outstanding care for patients with inherited bone marrow failure and acquired aplastic anemia during their transition from diagnostic evaluation to treatment through HSCT.
In coordination with these clinical efforts, his clinical research program seeks to retrospectively and prospectively assess HSCT outcomes for patients with inherited and acquired bone marrow failure syndromes and other non-malignant hematologic conditions, including sickle cell disease and thalassemia major. He is the lead/site Principal Investigator of several investigator-initiated and multicenter clinical trials of HSCT for these diseases, for which the ultimate goal is to define optimal approaches to transplant timing, donor choices, and graft engineering.
The goal of his laboratory research program is to improve HSCT outcomes by identifying methods to decrease the incidence of graft failure following HSCT, which is a particularly critical challenge in the setting of transplant for non-malignant conditions such as bone marrow failure. Methods are being examined to enhance donor hematopoietic stem cell engraftment efficiency following HSCT through enhancement of the functions of specialized areas of the bone marrow microenvironment, known as hematopoietic stem cell niches. Currently, therapeutic strategies are being tested that can be applied to enhance niche activity and receptivity for donor stem cells, which would in turn improve donor engraftment efficiency following clinical HSCT.
Education and Training
BA, Rice University (Biochemsitry and Cell Biology; Policy Studies), 1998
PhD, University of Virginia School of Medicine (Molecular Physiology), 2005
MD, University of Virginia School of Medicine, 2006
Fellowship, Children's Hospital of Philadelphia (Pediatric Hematology/Oncology), 2012
Titles and Academic Titles
Director of Research, Comprehensive Bone Marrow Failure Center
Assistant Professor of Pediatrics
American Society of Pediatric Hematology/Oncology, 2008-
American Society of Hematology, 2008-
American Society of Bone Marrow Transplant, 2011-
Abramson Cancer Center, 2014-
Clinical Care Consortium of Telomere-Associated Ailments, 2014-
Pediatric Blood and Bone Marrow Transplant Consortium, 2015-
The Richards Society of the University of Pennsylvania, 2016-
Blood and Marrow Transplant Clinical Trials Network, 2016-
Team Telomere, Medical Advisory Board, 2017-
American Society of Pediatric Hematology/Oncology Young Investigator Travel Award, 2011-
American Society of Hematology Research Training Award for Fellows, 2011-
Canuso Foundation Innovation Grant Award, Children's Hospital of Philadelphia, 2011
American Society of Bone Marrow Transplantation Travel Grant Award, 2012
The University of Pennsylvania and Children's Hospital of Philadelphia Institute of Translational Medicine an Therapeutics and Clinical and Translational Research Center Junior Investigator Pilot Grant Program Awardee, 2012
Alexandra J. Kefalides Memorial Prize for Research in Normal and Malignant Hematopoiesis, 2013
American Society of Hematology Scholar Award, 2014
Distinguished Teaching Award for Oncology, Pediatric Hematology/Oncology Fellowship Program, Children's Hospital of Philadelphia, 2017